retatrutide case study for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials Retatrutide Significantly Reduces Visceral Fat

Glickman, MD, explains that success on a GLP-1 medication is considered a body weight loss of more than 5% after three months of treatment

Understanding your medication schedule is essential for consistent weight loss results and managing side effects effectively

A competent prescriber understands obesity as a disease, the full medication toolkit, the controlled-substance compliance phentermine requires, the side-effect and lean-mass considerations semaglutide brings, and the program-level judgment that decides when to use one, the other, or both in sequence

You should not take retatrutide if you have: A personal or family history of medullary thyroid carcinoma Multiple Endocrine Neoplasia syndrome type 2 A history of pancreatitis Severe gastrointestinal disease, including gastroparesis Known hypersensitivity to any component of the drug You should use extreme caution and only proceed under close medical supervision if you have: Gallbladder disease or a history of gallstones Kidney disease, since dehydration from GI side effects can accelerate kidney damage Diabetic retinopathy, as rapid glucose changes can worsen it A history of eating disorders, since appetite suppression this powerful can interact badly with disordered eating patterns Retatrutide is also not approved for use in pregnancy

Side effects peak weeks 6-8